Tanvex BioPharma, Inc. (TPE:6541)
Taiwan
· Delayed Price · Currency is TWD 56.20
+1.20 (2.18%)
May 14, 2025, 11:31 AM CST
Tanvex BioPharma Revenue
Tanvex BioPharma had revenue of 49.86M TWD in the quarter ending March 31, 2025, with 1,385.31% growth. This brings the company's revenue in the last twelve months to 81.18M, up 134.43% year-over-year. In the year 2024, Tanvex BioPharma had annual revenue of 34.68M, down -43.53%.
Revenue (ttm)
81.18M
Revenue Growth
+134.43%
P/S Ratio
161.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
13.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.68M | -26.73M | -43.53% |
| Dec 31, 2023 | 61.41M | 39.01M | 174.11% |
| Dec 31, 2022 | 22.40M | 17.00M | 314.43% |
| Dec 31, 2021 | 5.41M | 5.11M | 1,702.00% |
| Dec 31, 2020 | 300.00K | - | - |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 11.34B |
| Caliway Biopharmaceuticals | 40.47M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 19.12B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Pegavision | 6.69B |
| Lumosa Therapeutics | 43.59M |